20 July 2026

Advanced Medical Solutions Group plc
("AMS" or the "Group")

Half Year 2026 Trading Update

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, today announces a trading update for the six months ended 30 June 2026.

The Board is pleased to announce that it expects to report half year 2026 revenues of approximately £115.2 million (H1 2025: £110.8 million), despite some first half orders shipping later than planned in early July. In addition, good progress in the Group's strategic focus of expanding direct sales in Europe has led to some de-stocking, with a consequential impact on sales in the period. As reported in our preliminary results on 18 March 2026, first half performance was against a high comparator caused by order phasing of one key strategic partner in the Advance Closure division in H1 2025.

The integration of Peters Surgical and Syntacoll remains on track.

The Board remains confident of delivering full year 2026 EBITDA in line with current market expectations.

Chris Meredith, Chief Executive Officer of AMS, said: "With our strengthened portfolio, and a pipeline of exciting and significant opportunities, we remain confident in the future prospects of the Group and delivering sustained long-term value."

– End –

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations	Tel: +44 (0) 1606 545508
Optimum Strategic Communications Mary Clark / Nick Bastin / Isabelle Abdou	Tel: +44 (0) 20 4566 8543 AMS@optimumcomms.com
Investec Bank PLC (NOMAD & Broker) Gary Clarence / Nick Prowting	Tel: +44 (0) 20 7597 5970
Berenberg (Joint Broker) Toby Flaux / Detlir Elezi	Tel: +44 (0)20 3207 7800

About Advanced Medical Solutions Group plc – see **www.admedsol.com**

AMS is an innovative tissue healing medical device company delivering high-performing solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.

AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear top-line trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.

Rule 28 of the Takeover Code

The UK Panel on Takeovers and Mergers has confirmed that this profit forecast constitutes an ordinary course profit forecast. The directors confirm that this profit forecast has been properly compiled and the basis of the accounting used is consistent with the Group's existing accounting policies. The profit forecast has been compiled on the basis of the assumptions set out in Part X *(AMS Profit Forecast)* of the Scheme Document and should therefore be read in this context and construed accordingly.